Conflict of Interest Disclosures Blood Advances

Transcription

1 Geoff Hill, MD Associate Editor Last Confirmed Date: 07/13/2016 Roche Clinical trial support 07/01/ Leslie Kean, MD, PhD Associate Editor Last Confirmed Date: Claudia Lengerke, MD Associate Editor Last Confirmed Date: 01/15/2018 Employment employment as physician-scientist in the Hematology/Oncology Department Max Eder Junior Group Leader Program 01/01/2038 project leader 09/01/2018 1

2 Nikhil C. Munshi, MD Associate Editor Last Confirmed Date: 07/10/2016 Amgen 01/01/2018 Celgene 01/01/2018 Celgene Celgene Celgene Celgene Honoraria Speakers Bureau Janssen 01/01/2018 Janssen Pharmaceutical Merck 01/01/2018 Millennium Millennium Novartis Novartis Honoraria Speakers Bureau Honoraria Speakers Bureau Oncopep 01/01/2019 Oncopep Oncopep Equity Ownership 01/01/2036 Oncopep Equity Ownership Oncopep Oncopep 01/01/2019 Oncopep Patents & Royalties 01/01/2019 Onyx Takeda 01/01/2018 2

3 Robert Negrin, MD Editor Last Confirmed Date: 02/01/2018 Equity Ownership Amgen 01/01/2020 BioEclipse Therapeutics Equity Ownership 01/01/2038 BioEclipse Therapeutics 01/01/2038 Cell Source 01/01/2036 Cell Source Equity Ownership 01/01/2036 Formula Formula Jazz Magenta Equity Ownership Equity Ownership Magenta UpToDate Julie A. Panepinto, MD, MSPH Associate Editor Last Confirmed Date: 01/31/2018 National Heart, Lung and Blood Institute HRSA I am a co-investigator (site PI) receiving research funding from this government agency. NIAMS I have NIH research funding from this institute. 09/30/ /31/2019 3

4 Margaret V. Ragni, MD, MPH Associate Editor Last Confirmed Date: 01/28/2018 Alnylam Honoraria This was to give talk for an online Medical Program for Investors. Alnylam This is for participation in phase 1, 2, 3 studies of novel bypass, sirna-at3, fitusiran. American Academy of CME Honoraria Moderator, Speaker for ASH Satellite Symposium: Clinica Challenges in von Willebrand Disease Management: Talk: "Managing the Bleeding Patient with VWD in the Emergency Department," San Diego CA, Dec 2, 2016 American Thrombosis Research Network ATHN American Thrombosis Research Network ATHN Baxalta/ Baxter Healthcare I have served on an advisory committee and a grants review committee. This supports clinical outcomes data collection, and support for clinical trials and observational studies in patients with bleeding disorders. Advisory Board for GI/Liver Disease (2010) Advisory Board for rvwf in Women's Health (2015-) 01/01/2036 Baxalta/ Baxter Healthcare Baxter Bioscience Honoraria 4

5 Baxter Bioscience 1.Research studies involving recombinant VWF in Von Willebrand disease. This provides funds to study dendritic cells in inducing tolerance in hemophilia A mice with inhibitors. 2.Dendritic cell vaccine in tolerance induction in hemophilia A mouse, Co-PI 3.Recombinant VWF PK and Safety study, 4.FVIIa BI Dose Escalation Study, Bayer Bayer Served on panel to research and discuss current problems in hemophilia. Bayer Bayer Research study of novel bypass agent BIogen 1.Research studies on long acting factor VIII and factor IX in hemophilia subjects. 2. Long-acting Factor IX, PK and safety Phase I/II study, 3. Long-acting Factor IX for phase III efficacy, 4. Long-acting Factor VIII, PK and Safety Phase I/II study, 5. Long-acting Factor VIII for phase III efficacy, Biogen Idec 01/01/ /01/ /01/2038 Biogen Idec Biogen Idec: Consultantancy I spoke as a hematologist to an investor's meeting regarding medical problems and potential benefits of a long-lasting clotting factors. Biogen Idec: Consultantancy I serve as a medical consultant to Biogen on a medical advisory board. 5

6 Biogen/Bioverativ Investigator-Initiated Research: To use FVIIIFc for ITI (HIRE trial) Research study of long-acting FVIIIFc-VWF-XTEN Biomarin This was for planning for a gene therapy trial. Biomarin This is a research trial of BMN gene therapy for hemophilia A. Bristol Myers Squibb Centers for Disease Control Hemophilia UDC, Clinical Outcomes, Co-investagator (Region III) Chiron (formerly Novartis) Long-term followup for retroviral VIII gene transfer in hemophilia, 01/01/2034 CSL Behring CSL Behring 1.Subcontract (UNC) Deep venous thrombosis in Hemophilia, 2.FVIIa-FP Phase III Trial in Hemophilia Inhibitor Patients, Co-Investigator Dimension Therapeutics This is for hemophilia gene therapy study. Foundation for Women and Girls with Blood Disorders Foundation for Women and Girls with Blood Disorders, Medical Advisory Board (2010- ) Genentech Roche This is for participation in a research trial of bispecific FVIII monoclonal antibody. Haemophilia Hematologist (ASH) Hemostasis Thrombosis Research Society Haemophilia, Editorial Board Member The Hematologist (ASH) Editorial Board Co-Chair Research Committee Board of Directors 6

7 Institute for Cost Effectiveness Research (ICER) Participation in review and public discussion of a white paper on cost-effectiveness of novel bypass Hemlibra (emicizumab) in hemophilia inhibitor patients. Johns Hopkins CME Honoraria Thrombosis Haemostasis Society of North American (THSNA) Symposium Speaker: "Improving Outcomes in Hemophilia A: Extended Half-life Factor VIII," Chicago IL, April 14, Journal of Rare Disorders Journal THrombosis Haemostasis I serve on the editorial board of The Journal of Rare Disorders. I serve on the JTH Editorial Advisory Board. MCHB HHS Region III Fed HTCs Hemophilia Diagnostic and Treatment Center, Medscape, Inc. Honoraria This was for speaking at ASH SuperFriday Symposium on Extended Half life Products for hemophilia. Medscape, Inc. National Hemophilia Foundation NHLBI This was for planning Educational programs on hemophilia for various venues. 1. NHF, Member MASAC 2. NHF, Women's Health Initiative, Member (2009-) 1. NHLBI HT Study Section , Member, Ad Hoc Member NHLBI State of the Science: Co-Chair Hemophli & VWD Subcommittee 3. ASH/NHLBI Worskhop on Recruitment,Retention of Hematologists 4. NHLBI Working Goup on HIV Research in Heart, Blood, Lung Diseases, /01/2036 7

8 NHLBI 1. (Subcontract St. Jude's Hospital) AAV-8 IX Gene Trial in Hemophilia, 2. (B2B) Mechanism of Hemolysis Activation in SCD,, (NIAID) Solid Organ Transplant in HIV+ Recipients, (PPG) Molecular and Clinical von Willebrand Disease, 5. (T35) T35 Training Students in Biomedical Research, Principal Investigator 6. Transfusion Medicine Hemostasis Network,, (K23) Multicenter Trial NovoNordisk OPKO Biologics Clinical Trial funding: Phase 1/2 Study to Assess Safety and Pharmacokinetics of Long Acting VIIa in Hemophilia A and B. PA Dept of Health State Hemophilia Program, Principal Investigator Pfizer FVIIa Variant in Hemophilia Inhibitor Patients Postgraduate Institute for Medicine Honoraria Planned, prepared, and presented webinar on inhibitor prevention and eradication in hemophilia. organized by NHF. Sangamo Research funding for clinical trial 01/01/2036 Shire Development LL Shire Development LL Shire is providing rvwf (Vonvendi) for my NIH-funded clinical trial in women with VWD. SPARK (formerly Children's Hospital of Philadelphia) Advisory Board on gene therapy data, trials, and future practice 01/01/2034 8

9 SPARK (formerly Children's Hospital of Philadelphia) AAV-2 IX Gene Trial in Hemophilia B, co-investigator AAV-8 FIX Gene trial in Hemophilia B, co-investigator AAV-8 VIII Gene trial in Hemophilia A, co-investigator 01/01/2034 Tacere Benitec Tacere Benitec I serve on a DSMB for a Tacere hepatitis C study. Tacere Benitec I serve on the DSMB for a hepatitis C clinical trial. Tacere Benitec Thrombosis Haemostasis Society of North America Vascular Medicine Institute Honoraria THSNA Symposia Plenary Session: Targeting sirna-at3: Novel Therapeutic for Hemophilia" Chicago IL, April 14, Vascular Medicine Institute, Scientific Advisory Board, University of Pittsbusrgh, member ) Vascular Medicine Institute Thrombin Generation in ITI Inhibitor Tolerance Study (PI) Anticoagulation in Acute Chest Syndrome (Mentor) rtpa Prevention of Central Line Thrombosis in Small Bowel Disease 01/01/ Wendy Stock, MD Associate Editor Last Confirmed Date: Amgen Genzyme Seattle Genetics 01/01/2036 9

10 Andrew S. Weyrich, PhD Associate Editor Last Confirmed Date: 01/08/2018 Nothing to disclose. 10